COVAXIN effective against Delta Plus variant of Covid-19: ICMR

The announcement comes amidst growing concerns over the third wave of coronavirus in India.

By Rajan Nath - August 02, 2021 1:08 pm

A study by the Indian Council of Medical Research (ICMR) revealed that India's indigenous Bharat Biotech's COVID-19 vaccine COVAXIN is effective against the Delta Plus variant of coronavirus, the ICMR said on Monday.

Delta Plus variant of coronavirus has been classified as a public health concern due to its impact on existing Covid-19 vaccines.

Also Read | ‘Things are going to get worse’ due to Covid-19, warns Dr Fauci

COVAXIN effective against Delta Plus variant of Covid-19: ICMR

The Delta variant has mutations that help it bind to the ACE2 receptors present on the surface of the cells more firmly. It makes it more transmissible and capable of evading the body's immunity.

Also Read | World is going through an education crisis due to Covid-19: UN chief

Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of  COVAXIN | DD News

Earlier, Bharat Biotech had stated that its Covid-19 vaccine 'Covaxin' has shown 77.8 percent effectiveness against Covid-19 and 65.2 percent protection against Delta variant.

The announcement comes amidst growing concerns over the third wave of coronavirus in India.

Coronavirus vaccine update: Bharat Biotech to manufacture vaccine in Odisha

The researchers have predicted that India may see another rise in Covid-19 cases soon in August with the third wave peaking with less than 100,000 infections a day or nearly 150,000 in the worst scenario.

A report stated that the rise in Covid-19 cases will lead to the third wave of coronavirus, which may peak in October.

-PTC News

adv-img
adv-img